Optina Diagnostics careers

In May 2019, Optina obtained Breakthrough Device Designation from the FDA for its test for the detection of the likely PET amyloid status (Positive or Negative). Optina is positioned to become a key step in the patient care path and to deliver value through this rapid and easily accessible Alzheimer disease detection platform.

Optina specializes in the development of technology for early, non-invasive detection of disease via Retinal Deep Phenotyping. With a primary focus on the diagnosis of Alzheimer’s disease, Optina addresses the need of millions of patients worldwide suffering from memory loss.

Currently, the diagnosis of Alzheimer’s relies on a variety of neurobehavioral tests that are subjective, as well as PET scans that are both expensive and inconvenient. Optina aims to establish a New Paradigm in dementia care by reducing time to accurate diagnosis from years to a few months with unparalleled precision. All while providing a clear care path and broad access for patients.